Dr. Oregonin secures FDA registration for OLTIS DENTAL‑X, launching a botanical oral‑care product grounded in a 1974 OSU discovery and two decades of South Korean research
Executive summary: Dr. Oregonin Inc. completed U.S. FDA registration for OLTIS DENTAL‑X, a botanical oral‑care product based on the oregonin compound discovered in 1974. The registration allows the product to be sold in the U.S. over‑the‑counter market, adding a new natural‑ingredient option to the oral‑care sector.
Who is involved: Dr. Oregonin Inc., Oregon State University (historical discovery), South Korean research partners.
Likely next: The firm can now proceed to market OLTIS DENTAL‑X in the United States.
On October 6, 2026, Dr. Oregonin Inc. announced that it had completed the U.S. FDA registration process for its OLTIS DENTAL‑X oral‑care formulation. The product combines the compound oregonin, first identified by Oregon State University in 1974, with 27 years of natural‑product research conducted by South Korean scientists. The registration permits the product to be marketed in the United States as an over‑the‑counter dental care item. This step adds a new botanical entrant to the competitive oral‑care market, potentially influencing consumer choice and ingredient sourcing trends.
Timeline
- — Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research (PR Newswire)
Analysis — what this means
Sectors affected
- oral-care product manufacturing
- botanical ingredient supply
- dental retail
Regulatory implications
- FDA registration classifies OLTIS DENTAL‑X as an over‑the‑counter drug under the Federal Food, Drug, and Cosmetic Act
Historical parallels
- 1974 Oregon State University discovery of the oregonin compound
- 27‑year natural‑product research program by South Korean scientists (circa 1999‑2026)
Key entities
Sources
Related cases
- Roche’s BTK inhibitor fenebrutinib gains FDA filing acceptance for both relapsing and primary progressive MS, marking a potential first-in-class oral therapy
- Food safety attorney pushes FDA for mandatory warning labels on raw sprouts following multi-state outbreak
- XtalPi files first IND for AI-discovered gut-restricted pan-TRK inhibitor, marking clinical-stage transition
- FDA approval of Fayuvi gene therapy marks a critical milestone for Ultragenyx's commercial trajectory and 2027 profit targets
- Clearmind Medicine engages with FDA in landmark psychedelic therapy hearing
- IASO Bio secures FDA clearance for first China-origin lentiviral in vivo CAR-T therapy